Results 111 to 120 of about 17,845 (225)

Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence

, 2017
FDA-approved integrase strand transfer inhibitors (raltegravir, elvitegravir and dolutegravir) efficiently inhibit HIV-1 replication. Here, we present fluorescence properties of these inhibitors.
Eric Deprez, Delelis, Olivier, Simon, Françoise, Thierry, Eloïse, Eloïse Thierry, Olivier Delelis, Lebourgeois, Samuel, Samuel Lebourgeois, Françoise Simon, Deprez, Eric   +9 more
core   +1 more source

Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts

Open Forum Infectious Diseases
Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according ...
T. Tiendrebeogo, Karen Malateste, Armel G Poda, A. Minga, E. Messou, H. Chenal, Oliver Ezechi, D. Ekouevi, I. Ofotokun, A. Jaquet   +9 more
semanticscholar   +1 more source

Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysisResearch in context

EClinicalMedicine
Summary: Background: Dolutegravir and bictegravir are frequently prescribed second-generation integrase strand transfer inhibitors. Although sex and gender influence drug pharmacokinetics, little is known about the differences in side effects ...
Zhou Fang, Tetiana Povshedna, Rowan Patterson, Erin Ready, Helene C.F. Cote, Melanie C.M. Murray, Elizabeth M. King   +6 more
doaj   +1 more source

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

, 2013
Dolutegravir is a second generation integrase strand transfer inhibitor (INSTI) currently under review by the US FDA for marketing approval. Dolutegravir’s in vitro, protein adjusted 90% inhibitory concentration (IC90) for wild-type virus is 0.064 μg/ml,
Hadzic, Tanja, Cottrell, Mackenzie L., Kashuba, Angela D.M.   +2 more
core   +1 more source

Metabolic Syndrome and Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy in Northern Tanzania

Journal of the International Association of Providers of AIDS Care
Purpose Chronic systemic inflammation from human immunodeficiency virus (HIV) may cause metabolic abnormalities in lipid metabolism. Additionally, the development of metabolic syndrome has been associated with specific anti-retroviral therapy ...
Tumaini E Mirai, K. Kilonzo, Abid M. Sadiq, I. A. Muhina, N. J. Kyala, Annette A Marandu, Sarah K Gharib, Andrea R Costantine, E. Mkwizu, William P. Howlett, E. Shao, G. Nyakunga, Huda F Akrabi, V. Kshettry, V. Maro, Nyasatu G. Chamba, Furaha S. Lyamuya   +16 more
semanticscholar   +1 more source

Dolutegravir use is related to lower HTLV-1 proviral load in people co-infected by HIV-1

Communications Medicine
Background Infection by human T-cell lymphotropic virus type 1 (HTLV-1) affects millions of people worldwide and causes severe diseases. To date, no specific treatment is available for HTLV infection. The purpose of this study was to determine the impact
Tatiana Fernandez, María B. Arriaga, Rafaela Mayoral, Eduardo M. Netto, Carlos Brites   +4 more
doaj   +1 more source

Body weight changes in people with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania

AIDS (London)
Objectives: To analyze weight changes associated with dolutegravir- versus efavirenz-based antiretroviral therapy (ART) in people with HIV (PWH) in rural Tanzania, where undernutrition is prevalent.
M. Weisser, H. Mapesi, F. Vanobberghen, J. Okuma, Anna Eichenberger, H. Wilson, Daniel H. Paris, A. Kalinjuma, E. Luoga, L. Wilson, T. R. Glass, F. Franzeck   +11 more
semanticscholar   +1 more source

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

, 2023
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy (ART) regimen has been associated with increased weight gain, which is markedly higher when combined with tenofovir alafenamide (TAF), the newer tenofovir prodrug ...
Mondleki, Enkosi
core  

HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST)

BMJ Open
Introduction HIV drug resistance poses a challenge to the United Nation’s goal of ending the HIV/AIDS epidemic. The integrase strand transfer inhibitor (InSTI) dolutegravir, which has a higher resistance barrier, was endorsed by the WHO in 2019 for first-
M. Egger, M. Sauermann, T. Loosli, Stefanie Hossmann, Selma Riedo, N. Beerenwinkel, Antoine Jaquet, A. Minga, Jeremy L Ross, J. Giandhari, R. Kouyos, R. Lessells   +11 more
semanticscholar   +1 more source

Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study

AIDS Research and Treatment
Conclusion: The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants.
Mohammed Jemal, Adane Adugna, Mamaru Getinet, Baye Ashenef, Gelagey Baye, Desalegn Abebaw, Zigale Hibstu Teffera, Wastina Bitewlign, Anemut Tilahun, Nuredin Chura Waritu, Tabarak Malik, Enyew Fenta Mengistu   +11 more
doaj   +1 more source